Extracorporeal membrane oxygenation (ECMO) is a temporary artifi cial extracorporeal support of the respiratory system and/or cardiac system used for the treatment of cardiopulmonary failure refractory to conven tional therapies. More than 1,000 papers on ECMO published between January 2009 and May 2011 (PubMed search) clearly indicate a renewed interest in the technique, initially triggered by the CESAR trial publication [1] and the recent H1N1 fl u pandemic. Indeed, during the pandemic the number of patients with acute respira tory distress syndrome (ARDS) who were not safely treatable with current clinical settings of mechanical ventilation (6 to 8 ml/kg tidal volume normalized on ideal body weight and plateau pressure lower than 30 to 35 cmH 2 O) and who therefore received extracorporeal respiratory support appeared to be greatly increased. After providing a brief background and some technical notes, we will review the most important and recent fi ndings related to the technique, its application and future applications.
Introduction
Extracorporeal membrane oxygenation (ECMO) is a temporary artifi cial extracorporeal support of the respiratory system and/or cardiac system used for the treatment of cardiopulmonary failure refractory to conven tional therapies. More than 1,000 papers on ECMO published between January 2009 and May 2011 (PubMed search) clearly indicate a renewed interest in the technique, initially triggered by the CESAR trial publication [1] and the recent H1N1 fl u pandemic. Indeed, during the pandemic the number of patients with acute respira tory distress syndrome (ARDS) who were not safely treatable with current clinical settings of mechanical ventilation (6 to 8 ml/kg tidal volume normalized on ideal body weight and plateau pressure lower than 30 to 35 cmH 2 O) and who therefore received extracorporeal respiratory support appeared to be greatly increased. After providing a brief background and some technical notes, we will review the most important and recent fi ndings related to the technique, its application and future applications.
Long-term ECMO, as support for severe respiratory failure, was fi rst successfully used in 1972 in an adult patient with post-traumatic respiratory failure [2] . A few years later, at the University of California, Bartlett and colleagues successfully treated a newborn with ECMO [3] . Th e enthusiasm for this new technique led to a randomized trial sponsored by the National Institutes of Health that compared venous-arterial ECMO with conventional mechanical respiratory support in severe ARDS [4] . After randomization of 90 patients the trial was stopped for futility because the mortality in both groups was around 90%. However, one should note that the greatest concern for mechanical ventilation, at that time, was the high fraction of inspired oxygen and not the high ventilator pressure/volume; that is, nonphysiological stress and strain. In this ECMO trial, therefore, the only diff erence in mechanical ventilation settings between treatment and control patients was a lower FiO 2 in the group that received the extracorporeal support. Moreover, the ECMO technology at these times was very primitive, with consistent risks for the patients due to high priming volumes of the extracorporeal circuits and elevated bleed ing risks associated with systemic anticoagulation. Th e limitations of this trial passed mostly unrecognized, however, and the discouraging results therefore led to the ECMO technique being abandoned worldwide.
During the same years, Kolobow was developing a new membrane lung optimized for carbon dioxide (CO 2 ) removal as a possible application in patients with chronic obstructive pulmonary disease. While testing this new device in spontaneously breathing animals, however, we observed when part of the metabolically produced CO 2
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The H1N1 fl u pandemic led to a wider use of extracorporeal membrane oxygenation (ECMO), proving its power in hypoxemic emergencies. The results obtained during this pandemic, more than any randomized trial, led to the worldwide acceptance of the use of membrane lungs. Moreover, as centers that applied this technique as rescue therapy for refractory hypoxemia recognized its strength and limited technical challenges, the indications for ECMO have recently been extended. Indications for venovenous ECMO currently include respiratory support as a bridge to lung transplantation, correction of lung hyperinfl ation during chronic obstructive pulmonary disease exacerbation and respiratory support in patients with the acute respiratory distress syndrome, possibly also without mechanical ventilation. The current enthusiasm for ECMO in its various aspects should not, however, obscure the consideration of the potential complications associated with this life-saving technique, primarily brain hemorrhage [5] . Artifi cial CO 2 removal could therefore be a powerful and valuable tool to control the respiratory drive up to complete apnea [6] . Indeed, the focus of extracorporeal support was shifted from oxygenation to CO 2 removal, aiming to provide lung rest to allow better healing. Th e hypothesis of limiting potential harmful stimuli was based uniquely on common sense, however, since concepts such as baby lung [7] , atelectrauma [8] , and so forth, were still unknown. Th e fi rst applications in humans of the concept of lung rest were reported in 1980 [9] . Soon after this experience a larger series of patients treated with extracorporeal CO 2 removal and low-frequency positive-pressure ventilation was described by the same authors [10] . However, a small randomized trial conducted in the United States at the beginning of the 1990s failed to show an outcome advantage of additional extracorporeal support as compared with conventional mechanical ventilatory support [11] . Despite this lack of evidence, a few centers around Europe continued to provide veno-venous extracorporeal support in selected series of patients, usually as a last resort [12] . In contrast, in the United States Bartlett and colleagues continued to provide extracorporeal support with stan dard mechanical ventilation, with more liberal indica tions and with encouraging results [13, 14] .
A renewed interest in this technique arose after the publication of the CESAR trial, which clearly showed an improvement in the death rate and severe disability 6 months after randomization, when patients with severe respiratory failure were treated with extracorporeal support in an expert high-case-volume center compared with nonspecialized hospital care [1] . Moreover, although not the primary outcome, an actual diff erence in survival of around 25% was observed for patients considered for ECMO treatment at 28 days, the primary outcome of most ARDS literature. However, the fi nal explosion of the application of this extracorporeal support was due to the use of ECMO as a rescue therapy in Australia and New Zealand during the H1N1 infl uenza pandemic [15] . Th is increased use is also probably due to several technical improvements, which allowed a simpler and safer use of the technique. Among these innovations we can mention the introduc tion of nonporous hollow fi ber devices, charac terized by low resistance to blood fl ow, and polymethyl pentene fi bers that, combined with nonthrombogenic coatings, decrease the need for platelet transfusion and continuous heparin infusion. Moreover, recently introduced wire-reinforced walls of vascular access devices allow very thin cannula walls, reducing resistance to blood fl ow.
As the acronym ECMO includes several techniques with diff erent aims, a brief reminder of the artifi cial lung's physiology is indicated to fully understand the diff erent approaches, before discussing the latest reports on the topic.
Physiology of the artifi cial lung
Oxygenation Th e amount of oxygen provided via artifi cial lung is a direct function of the blood fl ow. Th e blood fl ow required during veno-venous bypass to achieve acceptable arterial oxygenation is usually between 3 and 6 l/minute, partially depending on the cardiac output of the patient, on the hemoglobin concentration and on saturation. Of note, the gas fl ow required to fully oxygenate the incoming blood through the artifi cial lung may be quite low. For example, if we consider an entering hemoglobin saturation of 60% (with 3 l/minute extracorporeal blood fl ow, 10 g/dl hemoglobin concentration, 40 mmHg partial pressure of oxygen in venous blood and approximately 85 ml/l oxygen content), to reach 100% saturation we would need 200 ml/minute oxygen. Providing 0.2 l/minute pure oxygen to a highly effi cient membrane lung would therefore theoretically be suffi cient. Th is underlines the fact that what is of primary importance for artifi cial oxygenation is the extracorporeal blood fl ow passing through the membrane lung, and not its ventilation.
Th e eff ects of the oxygen supplied by the membrane lung on systemic oxygenation depend on the type of cannulation and on the possible changes induced by the artifi cial oxygenation on the function of the native lung. In a veno-venous circuit the artifi cial lung is in series with the natural lung. Th e improvement in arterial oxygenation, in this case, is due to the increased oxygen saturation of the blood fl owing through shunt regions of the natural lung. Great improvements from oxygenation can therefore not be expected. Moreover, with this type of vascular access, as blood with high oxygen saturation reaches the pulmonary artery, the shunt fraction of the natural lung usually increases due to the loss of hypoxic vasoconstriction [16] . Despite this, the veno-venous approach with high fl ow, even with very high shunt in the natural lung, provides vital arterial oxygenation.
Th e veno-arterial approach, mostly used for cardiac support, implies the drainage of venous blood, its oxygenation and the subsequent input in the arterial tree through a cannulated artery. Th e improvement of systemic oxygenation with this technique is much better as compared with the veno-venous approach because the artifi cially oxygenated blood mixes with arterial blood and directly perfuses distal organs. Moreover, in this type of cannulation -the artifi cial lung being in parallel with the natural lung -there is no loss of hypoxic vasoconstriction, because no highly oxygenated blood enters the pulmonary artery. Despite the unique ability to also provide cardiac support, this type of cannulation is characterized by major disadvantages. First, an arterytypically the femoral artery -has to be cannulated with a large vascular catheter. Th is greatly increases the risk of ischemia of the inferior limb. Moreover, the aim of extracorporeal oxygenation (that is, to provide adequate oxygen supply to vital organs such as the brain and the heart) cannot be guaranteed through veno-arterial support if the input of oxygenated blood is performed distal to the great vessels; that is, through the femoral artery [16] .
Carbon dioxide removal
Th e removal of CO 2 is primarily a function of the fl ow of fresh gas. Th eoretically it is possible to remove all of the metabolically produced CO 2 (rate of elimination of CO 2 about 200 to 250 ml/minute) from 0.5 to 1 l/minute venous blood due to its high CO 2 content (1 l of venous blood at partial pressure of CO 2 45 mmHg and pH 7.38, in standard conditions, contains about 500 ml CO 2 ). In this regard, the local acidifi cation of entering blood may further enhance CO 2 removal [17] . In the artifi cial lung, therefore, while high extracorporeal blood fl ow is required and low gas fl ow is suffi cient for oxygenation, for CO 2 removal very low extracorporeal blood fl ow is suffi cient and high gas fl ow is required.
Th e extracorporeal CO 2 removal allows the lungs to be put to rest, abolishing totally or partially the need for ventilation [18] . Indeed, if the main purpose of the applica tion of the artifi cial lung is to allow lung rest and a gentle ventilation of the baby lung, low extracorporeal blood fl ows are suffi cient [19] . In general, lower blood fl ow is feasible with smaller endovascular catheters and is associated with lower technical diffi culties and complications. Th e approach of arterio-venous bypass with a pumpless device allows consistent CO 2 removal at the price of an arterio-venous fi stula [20] [21] [22] . Low-fl ow CO 2 removal systems coupled to or uncoupled from hemofi ltration may remove 20 to 30% of the rate of metabolically produced CO 2 [23] [24] [25] [26] . With artifi cial lungs actually available, total CO 2 clearance requires a blood fl ow in the order of 1 to 2 l/minute. Moreover, it is conceivable and desirable that, in the near future, regional anticoagulation (for example, with sodium citrate) will be available and will therefore greatly reduce the risk for bleeding due to systemic heparin infusion [27] .
The H1N1 fl u pandemic
Th e rebirth of extracorporeal respiratory support is primarily due to its use as a rescue therapy for lifethreatening hypoxemia in Australia and New Zealand during the H1N1 fl u pandemic [15] . Th e proper choice for such a purpose was therefore a veno-venous bypass with large-bore drainage catheters to allow high blood fl ows. Th e overall survival rate in this selected population was higher than 70%. After this report and in light of results from the CESAR trial [1] , an impressive number of centers started to use this technique despite some scientists having expressed some doubt on the scientifi c evidence of its outcome advantages. Th e only evidence that led to the application of ECMO was the presence of moribund, severely hypoxemic patients that did not benefi t from maximal mechanical ventilatory support [28] [29] [30] [31] [32] . Interestingly this technique was applied in Europe, the United States, South America, Canada and Asia, spreading as the H1N1 pandemic [33] [34] [35] [36] [37] [38] . More than 1,000 papers were published from 2009 to May 2011; however, most articles were not related to the use of ECMO in H1N1 fl u but referred for other indications, such as lung hyperinfl ation, cardiac failure or severe respiratory failure not caused by H1N1.
Extracorporeal support is a tool to buy time, maintaining life while awaiting improvement of the underlying disease. Th erefore, it is theoretically crucial to take advan tage of the extracorporeal support to minimize or, even better, to abolish the possible harm caused by an injurious mechanical ventilation. Extracorporeal CO 2 removal, in fact, partially or totally abolishes the need for ventilation, allowing one to apply a gentle ventilatory approach. It would therefore be interesting to know how mechanical ventilation was performed during extracorporeal support in the latest published studies. Surprisingly, however, the details on settings of mechanical ventilators are diffi cult to retrieve because when some mention of mechanical ventilation is made the infor mation is limited to a general agreement with ARDS Network suggestions [39] . Some papers specifi ed more details, which are still in line with lung-protective strategies aiming for a further reduction of tidal volume (for example, 3 to 5 ml/kg ideal body weight) while maintaining relative high mean airway pressure by high positive end-expiratory pressure (PEEP). In this scenario, however, we may fi nd extreme diff erences [15, 36, [40] [41] [42] . As an example, in several centers in Italy it was not uncommon to observe very low tidal volumes with the respiratory rate limited to 7 or 8 breaths/minute and a high mean airway pressure related to high PEEP application. On the other hand, in other units -for example at the Karolinska Institute of Stockholm -the patients are kept awake with 5 cmH 2 O PEEP and ventilated with pressure support of 20 to 25 cmH 2 O (personal communication, Dr Palmér, Section Manager of the ECMO Center, Karolinska Institute, Stockholm, Sweden). In our ICU in Milan, patients were treated initially with high PEEP, above 15 cmH 2 O, and lowfrequency ventilation [34] . To date, however, it is impossible to claim the superiority of a given treatment of the native lung during extracorporeal respiratory support as no studies are available on the topic. Th is lack of studies is primarily due to the scarcity of the patient population. However, it is important to emphasize -at least with regard to H1N1 patients -that the survival rate ranged from 56 to 79% throughout the centers, indepen dent of the applied strategy of mechanical ventilation [15, 33, 34, 36] .
We may therefore ask ourselves what we learned after this impressive utilization of extracorporeal support. First, extensive use of this technique all over the world in H1N1 patients confi rmed that extracorporeal support is associated with high survival rates in severe hypoxemic patients. More over, we learned that these moribund patients may start time-buying extracorporeal respiratory support in the hospital of origin and thereafter be safely transferred to the referral ECMO centers. Th is practice has been clearly documented in Scandinavia [42, 43] as well as in Italy [44] .
Indications

Acute respiratory distress syndrome
After these considerations we may now discuss the actual indications for ECMO. Th e choice of the technique, which may vary from low-fl ow bypass with CO 2 removal to highfl ow ECMO with total oxygenation support, depends on the patient's situation and the physician's preference.
Extracorporeal assistance as a rescue therapy
If the aim is the treatment of life-threatening hypoxemia, the clear-cut indication is high-fl ow veno-venous ECMO. If the patient presents with severe cardiac failure, however, veno-arterial ECMO must be used. Th e obvious question is whether these types of treatment are associated with a better outcome.
Th e recently published CESAR trial provided some clues in this regard [1] . Many physicians, however, were not fully convinced by the investigators' approach [45] [46] [47] . In fact, this pragmatic study really tested the diff erences in outcome between a specialized center with high-volume activity and single centers with low-volume activity. Despite these limitations the study strongly indicated that treatment with extracorporeal support may increase the survival rate in a selected population of patients with ARDS. We may ask ourselves why, after over 30 years, a classical, adequately powered randomized trial has not been conducted in these severely hypoxemic patients. To test a possible mortality diff erence of 10% between the ECMO and control arms would require enrollment of about 1,000 patients (with 90% power using a cutoff value for statistical signifi cance of 0.05). Given that the enrollment rate of previous large randomized trials on severe ARDS [48] [49] [50] [51] was approximately 0.3 patients/unit/month and that only one-third of these patients could have met the criteria for ECMO application -that is, severe refractory hypoxemia (partial pressure of oxygen <100 mmHg despite 100% FiO 2 ) [52] -20 ECMO centers would take over 40 years to complete the study (the CESAR trial took about 8 years). It therefore seems to us that a classical randomized trial is not feasible.
Despite this, there seems a high likelihood that extracorporeal support has saved the lives of some extremely severe patients. ECMO seems to be indicated in this type of patient because the risks from complications of the technique seem irrelevant when almost certain death can be predicted. Th e question is diff erent when severe hypoxemia is still manageable with more conventional approaches (high PEEP, high-frequency oscillatory ventilation, 100% FiO 2 , nitric oxide, and so forth). In these patients, the possible benefi ts of extra corporeal support have to be balanced with the only lethal complication of ECMO, which is intracranial hemorrhage. Unfortunately there are few data to predict with reasonable confi dence the incidence of intracranial hemorrhage in adults [53] . According to the Italian ECMOnet experience, intracranial hemor rhage occurred in one patient out of 49 (personal com muni cation, Dr Patroniti, San Gerardo Hospital, Monza, Italy). In our experience, however, the incidence was about 5% and this complication occurred both in subjects treated for hematologic malignancy and in patients with no predictable cause of increased bleeding susceptibility. Any time we consider a patient for ECMO we must therefore keep in mind this unpredictable and lethal complication.
Extracorporeal assistance to provide lung rest
If the aim of applying the artifi cial lung is not to assure oxygenation during hypoxemic emergency but to assure complete lung rest or to allow a protective lung strategy, CO 2 removal is indicated. A technique that solely removes CO 2 is applied in arterio-venous bypass [22] . With this technique the extra corporeal blood fl ow is low and oxygen transfer negligible, the input blood in the oxygenator being arterial and therefore already highly saturated. In our opinion, however, in ARDS patients it is safe to remove CO 2 using devices that also allow the performance of blood fl ows up to 2 to 2.5 l/minute. In this way, if needed, not only may lung rest be provided but also oxygenation maintained, in case of natural lung function deterioration.
Extracorporeal assistance for indications other than ARDS
Increased confi dence in using extracorporeal assistance led to use of the technique in diff erent clinical conditions. Although outside the aim of the present review, the following conditions should be noted.
Bridge to lung transplant
Extracorporeal assistance has been successfully used as a bridge to lung transplant in patients with terminal chronic obstructive pulmonary disease or cystic fi brosis. Of note, there is an increased tendency to maintain those patients awake, and spontaneously breathing, without the need for intubation [54] .
Lung hyperinfl ation
Lung hyperinfl ation is common during chronic obstructive pulmonary disease exacerbation or during status asthmaticus. In this condition, when noninvasive mechanical ventilation fails, extracorporeal support may be applied. Th e primary aim is to remove CO 2 , therefore reducing spontaneous ventilation and allowing progressive lung defl ation [55] .
Cardiac failure
Th ere is much experience providing extracorporeal assistance during cardiogenic shock. In this condition the approach is obviously venous-arterial, providing not only respiratory but also cardiac assistance.
Conclusion
Recent events moved the spots of scientifi c interest once again on extracorporeal techniques of respiratory support. Since the fi rst experiences with ECMO, technology has hugely evolved, making extracorporeal respiratory support safer and more cost-eff ective. Indeed, extracorporeal respiratory support is now an attractive strategy for the treatment of any type of respiratory failure in addition to, or even as an alternative to, mechanical ventilation.
